ClinicalTrials.gg
WithdrawnNCT04667871Updated Dec 16, 2020

Effect of Cataract Hyperemulsification Surgery on Meibomian Gland Morphology and Function

An observational study in Meibomian Gland Dysfunction, sponsored by Yune Zhao. Withdrawn. Open to participants aged 38 Years to 87 Years. Per ClinicalTrials.gov, last updated 2020-12-16.

Sponsored by Yune Zhao · Observational

Why this study was withdrawn
An six-month follow-up was completed after the treatment
Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
0
Ages
38 Years to 87 Years
Sex
All
01

Study summary

50 participants at Eye Hospital of Wenzhou Medical University during August, 2017 to July, 2020 will be enrolled in this study. To study the effect of cataract supermammary surgery on the morphology and function of meibomian glands

02

Conditions studied

  • Meibomian Gland Dysfunction

Keywords

  • meibomian gland
  • cataract surgery
03

In context

Meibomian Gland Dysfunction

172 studies on the registry are indexed under Meibomian Gland Dysfunction; 23 are open to participants now.

Browse Meibomian Gland Dysfunction studies →

Lead sponsor

Yune Zhao is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
38 Years to 87 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Those patients who undergoing cataract hyperemulsification surgery and previously untreated with xerophthalmia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously untreated patients with xerophthalmia
  • Undergoing cataract hyperemulsification surgery

Exclusion criteria

Exclusion Criteria:

  • No history of ocular surgery and trauma
  • Any eye diseases except xerophthalmia
  • No treated for xerophthalmia before
  • Successful completion of follow-ups
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
0 participants (actual)
Patient registry
No

Groups and cohorts

  • Eyes for cataract surgery

    Eyes for cataract surgery

    Procedure: cataract surgery

  • Eyes without cataract surgery

    Eyes without cataract surgery

Interventions

  • Procedurecataract surgery

    Eyes for cataract surgery

06

What researchers measure

Primary outcomes

  1. OSDI scale survey

    OSDI scale survey

    Time frame: 08/2017 to 07/2020

  2. tear meniscus height(mm)

    tear meniscus height(mm)

    Time frame: 08/2017 to 07/2020

  3. first tear film rupture time(s)

    first tear film rupture time(s)

    Time frame: 08/2017 to 07/2020

  4. average tear film rupture time(s)

    average tear film rupture time(s)

    Time frame: 08/2017 to 07/2020

  5. the range of meibomian gland missing(%)

    the range of meibomian gland missing(%)

    Time frame: 08/2017 to 07/2020

  6. meibomian gland average diameter (mm)

    meibomian gland average diameter (mm)

    Time frame: 08/2017 to 07/2020

  7. meibomian gland length (mm)

    meibomian gland length (mm)

    Time frame: 08/2017 to 07/2020

  8. meibomian gland area (mm^2)

    meibomian gland area (mm\^2)

    Time frame: 08/2017 to 07/2020

  9. meibomian gland deformation coefficient

    meibomian gland deformation coefficient

    Time frame: 08/2017 to 07/2020

  10. meibomian gland total proportion of glands (%)

    meibomian gland total proportion of glands (%)

    Time frame: 08/2017 to 07/2020

  11. meibomian gland imaging value

    meibomian gland imaging value

    Time frame: 08/2017 to 07/2020

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04667871
Lead sponsor
Yune Zhao
Responsible party
Yune Zhao (Vice president of Eye Hospital of Wenzhou Medical University, Wenzhou Medical University) — Sponsor-investigator
First posted
Dec 16, 2020
Start date
Aug 1, 2017
Primary completion
Jul 1, 2020
Completion
Sep 1, 2020
Last update
Dec 16, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion